vs

Side-by-side financial comparison of BayCom Corp (BCML) and PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $25.9M, roughly 1.7× BayCom Corp). BayCom Corp runs the higher net margin — 26.5% vs -90.4%, a 116.9% gap on every dollar of revenue. On growth, PACIFIC BIOSCIENCES OF CALIFORNIA, INC. posted the faster year-over-year revenue change (13.8% vs 9.4%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $-19.9M). Over the past eight quarters, PACIFIC BIOSCIENCES OF CALIFORNIA, INC.'s revenue compounded faster (7.3% CAGR vs 2.9%).

BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

BCML vs PACB — Head-to-Head

Bigger by revenue
PACB
PACB
1.7× larger
PACB
$44.6M
$25.9M
BCML
Growing faster (revenue YoY)
PACB
PACB
+4.4% gap
PACB
13.8%
9.4%
BCML
Higher net margin
BCML
BCML
116.9% more per $
BCML
26.5%
-90.4%
PACB
More free cash flow
BCML
BCML
$50.0M more FCF
BCML
$30.1M
$-19.9M
PACB
Faster 2-yr revenue CAGR
PACB
PACB
Annualised
PACB
7.3%
2.9%
BCML

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BCML
BCML
PACB
PACB
Revenue
$25.9M
$44.6M
Net Profit
$6.9M
$-40.4M
Gross Margin
37.1%
Operating Margin
36.6%
-92.3%
Net Margin
26.5%
-90.4%
Revenue YoY
9.4%
13.8%
Net Profit YoY
12.1%
-1802.7%
EPS (diluted)
$0.63
$-0.11

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCML
BCML
PACB
PACB
Q4 25
$25.9M
$44.6M
Q3 25
$25.7M
$38.4M
Q2 25
$24.7M
$39.8M
Q1 25
$24.3M
$37.2M
Q4 24
$23.7M
$39.2M
Q3 24
$25.6M
$40.0M
Q2 24
$23.8M
$36.0M
Q1 24
$24.5M
$38.8M
Net Profit
BCML
BCML
PACB
PACB
Q4 25
$6.9M
$-40.4M
Q3 25
$5.0M
$-38.0M
Q2 25
$6.4M
$-41.9M
Q1 25
$5.7M
$-426.1M
Q4 24
$6.1M
$2.4M
Q3 24
$6.0M
$-60.7M
Q2 24
$5.6M
$-173.3M
Q1 24
$5.9M
$-78.2M
Gross Margin
BCML
BCML
PACB
PACB
Q4 25
37.1%
Q3 25
41.4%
Q2 25
36.9%
Q1 25
-3.7%
Q4 24
25.6%
Q3 24
25.0%
Q2 24
16.5%
Q1 24
29.1%
Operating Margin
BCML
BCML
PACB
PACB
Q4 25
36.6%
-92.3%
Q3 25
26.3%
-101.1%
Q2 25
35.3%
-112.8%
Q1 25
31.6%
-1154.5%
Q4 24
34.2%
-390.1%
Q3 24
32.4%
-160.3%
Q2 24
31.9%
-488.3%
Q1 24
33.3%
-209.6%
Net Margin
BCML
BCML
PACB
PACB
Q4 25
26.5%
-90.4%
Q3 25
19.5%
-98.9%
Q2 25
25.8%
-105.4%
Q1 25
23.4%
-1146.8%
Q4 24
25.9%
6.0%
Q3 24
23.5%
-151.9%
Q2 24
23.6%
-481.3%
Q1 24
24.0%
-201.4%
EPS (diluted)
BCML
BCML
PACB
PACB
Q4 25
$0.63
$-0.11
Q3 25
$0.46
$-0.13
Q2 25
$0.58
$-0.14
Q1 25
$0.51
$-1.44
Q4 24
$0.55
$-0.44
Q3 24
$0.54
$-0.22
Q2 24
$0.50
$-0.64
Q1 24
$0.51
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCML
BCML
PACB
PACB
Cash + ST InvestmentsLiquidity on hand
$279.5M
Total DebtLower is stronger
Stockholders' EquityBook value
$338.6M
$5.3M
Total Assets
$2.6B
$784.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCML
BCML
PACB
PACB
Q4 25
$279.5M
Q3 25
$298.7M
Q2 25
$314.7M
Q1 25
$343.1M
Q4 24
$389.9M
Q3 24
$471.1M
Q2 24
$509.8M
Q1 24
$561.9M
Stockholders' Equity
BCML
BCML
PACB
PACB
Q4 25
$338.6M
$5.3M
Q3 25
$334.3M
$36.1M
Q2 25
$330.6M
$61.5M
Q1 25
$329.3M
$91.6M
Q4 24
$324.4M
$506.6M
Q3 24
$321.7M
$453.1M
Q2 24
$315.3M
$492.7M
Q1 24
$314.2M
$649.0M
Total Assets
BCML
BCML
PACB
PACB
Q4 25
$2.6B
$784.1M
Q3 25
$2.6B
$803.2M
Q2 25
$2.6B
$825.5M
Q1 25
$2.6B
$860.8M
Q4 24
$2.7B
$1.3B
Q3 24
$2.6B
$1.5B
Q2 24
$2.6B
$1.5B
Q1 24
$2.6B
$1.7B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCML
BCML
PACB
PACB
Operating Cash FlowLast quarter
$31.8M
$-19.1M
Free Cash FlowOCF − Capex
$30.1M
$-19.9M
FCF MarginFCF / Revenue
116.2%
-44.6%
Capex IntensityCapex / Revenue
6.7%
1.9%
Cash ConversionOCF / Net Profit
4.64×
TTM Free Cash FlowTrailing 4 quarters
$51.1M
$-114.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCML
BCML
PACB
PACB
Q4 25
$31.8M
$-19.1M
Q3 25
$7.3M
$-18.7M
Q2 25
$6.4M
$-29.4M
Q1 25
$9.3M
$-44.1M
Q4 24
$30.4M
$-30.6M
Q3 24
$9.6M
$-45.5M
Q2 24
$7.7M
$-54.3M
Q1 24
$5.1M
$-75.7M
Free Cash Flow
BCML
BCML
PACB
PACB
Q4 25
$30.1M
$-19.9M
Q3 25
$6.2M
$-18.8M
Q2 25
$5.6M
$-29.9M
Q1 25
$9.1M
$-45.4M
Q4 24
$28.7M
$-32.3M
Q3 24
$9.4M
$-46.3M
Q2 24
$7.4M
$-55.7M
Q1 24
$3.9M
$-79.6M
FCF Margin
BCML
BCML
PACB
PACB
Q4 25
116.2%
-44.6%
Q3 25
24.3%
-48.9%
Q2 25
22.8%
-75.3%
Q1 25
37.6%
-122.3%
Q4 24
121.1%
-82.3%
Q3 24
36.6%
-115.7%
Q2 24
31.2%
-154.8%
Q1 24
16.1%
-205.0%
Capex Intensity
BCML
BCML
PACB
PACB
Q4 25
6.7%
1.9%
Q3 25
4.3%
0.2%
Q2 25
3.0%
1.4%
Q1 25
0.6%
3.7%
Q4 24
7.2%
4.1%
Q3 24
1.0%
2.0%
Q2 24
1.0%
4.1%
Q1 24
4.7%
10.0%
Cash Conversion
BCML
BCML
PACB
PACB
Q4 25
4.64×
Q3 25
1.47×
Q2 25
1.00×
Q1 25
1.63×
Q4 24
4.96×
-12.93×
Q3 24
1.60×
Q2 24
1.37×
Q1 24
0.86×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCML
BCML

Segment breakdown not available.

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

Related Comparisons